September 18, 2023Open Access

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

ICI-induced AI is a rare irAE, and close monitoring of cortisol levels is important. Patients diagnosed with AI after receiving immunotherapy seem to have a favorable outcome.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Xiang et al. (Mon,) studied this question.

synapsesocial.com/papers/69da2b01387cf70698686720 https://doi.org/https://doi.org/10.1016/j.tranon.2023.101787

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma2014 · 287 citations
2Immunosuppression for ipilimumab-related toxicity can cause <i>pneumocystis</i> pneumonia but spare antitumor immune control2015 · 45 citations
3Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center2015 · 1,076 citations
4Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy2016 · 39 citations
5Adrenal insufficiency following nivolumab therapy in patients with recurrent or metastatic head and neck cancer2019 · 12 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo